Update on the clinical relevance of the C-reactive protein in Forum Sanitas
25.04.2023
An update on the clinical relevance of the C-reactive protein was published in the second edition of 2023 in the medical magazine Forum Sanitas. Dr. Wolfgang Ries and Dr. Fabrizio Esposito report from the practice of therapies for acute, necrotic pancreatitis and severe myocardial infarction.
Pentracor at the annual convention of the German Cardiac Society
19.04.2023
We have been at the 89th annual convention of the German Cardiac Society in Mannheim where we had great conversations with new and old contacts in the cardiologists community.
Pentracor titled as innovative and presented in the IGG WB newsletter
09.09.2022
The IGG WB current newsletter of the Brandenburg Healthcare Initiative, issue 2/2022, reports on Pentracor GmbH and describes it as innovative.
Pharmacy magazine Mylife reports on CRP apheresis in heart attacks
Berlin, 03.06.2022
The pharmacy magazine Mylife has published an interview with a heart attack patient and his doctor. Our managing director also has his say here. The original article can be found on pages 52 - 45 of issue 11/2022.
Second part of the second episode of our podcast has been published on YouTube
19.05.2022
Pentracast is the name of our new, informative podcast in which various employees, users and many others answer questions from our medical device consultant Henrike Weß.
This is the second part of the conversation between Henrike and Oliver
German Journal "Ärzteblatt" on C-reactive protein
01.04.2022
Today the north-eastern German journal reports on C-reactive protein
Published Papers
Neue Publikation: CRP-Apherese bei cardiogenem Schock
11.12.2023 Im CAMI-Register werden die Daten von Herzinfarktpatienten gesammelt, die mit der CRP-Apherese behandelt wurden. In diesem Rahmen konnten auch Daten von Patienten mit cardiogenem Schock gewonnen werden. Die Ergebnisse der ersten 10 Patienten (9 wurden reanimiert) wurden nun in Frontiers in Drug Discovery veröffentlicht. Obwohl bei cardiogenem Schock mit einer hohen Krankenhausmortalität zu rechnen…
CRP-Apherese im medizinischen Alltag angekommen
10.12.2023 Im Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie, einer der ältesten deutschen Fachzeitschriften im Bereich Arbeit, Umwelt, Gesundheit und Sicherheit, wurde ein Artikel über das C-reaktive Protein veröffentlicht. Dort wird unter anderem die schädliche Rolle des CRP bei ischämischen Vorfällen hervorgehoben und auch die CRP-Apherese als Therapiemöglichkeit genannt. Den Originalartikel C-reaktives Protein (CRP) – ein…
New publication: Being Eaten Alive
16.08.2023
In tissues with insufficient oxygen supply, CRP initiates the disposal of vital cells. They are being eaten alive. This leads to damage, e.g. after heart attack. Therefore, CRP is obviously a therapeutic target molecule.
New publication about CRP as a target for therapy to reduce inflammation
26.07.2023
Frontiers in Immunology published an article by three Canadian authors on CRP as a therapeutic target.
New publication on CRP apheresis as a therapeutic option in STEMI
11.07.2023
The cardiac MRI tissue characteristics of myocardial damage correlate with the extent of left ventricular dysfunction in the acute phase of severe myocardial infarction (STEMI). Since lowering CRP levels leads to smaller infarcts and better heart function, it could be considered as an additional therapeutic option in STEMI.
New comment on CRP apheresis
22.03.2023
An article entitled “C-reactive Protein Apheresis in Acute Myocardial Infarction” was published in the journal Current Pharmaceutical Design, April 2023 issue, and addresses the topic of C-reactive protein apheresis (CRP-A) therapy in patients with acute myocardial infarction.
Awards
Positive assessment of the potential of CRP apheresis by the G-BA
16.05.2023
Zum Klären der Effizienz der CRP-Apherese-Therapie hat sich die Pentracor GmbH bereits im November 2022 an den G-BA (Gemeinsamer Bundesausschuss, das oberste Beschlussgremium der gemeinsamen Selbstverwaltung im deutschen Gesundheitswesen) gewendet.
Pentracor CAMI-1 study praised as groundbreaking
11.01.2022
The authors of the review article “Immune Mechanisms of Plaque Instability” from the Charité Cardiology Department describe the Pentracor CAMI-1 study “CRP apheresis in Acute Myocardial Infarction” as groundbreaking.
Ahmed Sheriff named one of the most important Brandenburgers in 2022
03.01.2022
The MOZ names our managing director the “most important Brandenburger”
Pentracor was awarded the "Zukunftspreis Brandenburg" 2021
12.11.2021
Pentracor was awarded the "Zukunftspreis Brandenburg" 2021!
A total of six companies and one special prize winner were awarded the state's most important business prize, the "Zukunftspreis Brandenburg" 2021. With their business ideas and developments, they convinced the top-class jury of 16 of their special achievements for the Brandenburg economy. Brandenburg's Minister President Dr. Dietmar Woidke congratulated the winners at the Holiday Inn Berlin Airport Conference Centre in Schönefeld and pointed out the importance of regional companies for the entire state of Brandenburg. In several rounds, they prevailed against a total of 82 applicants.
German Medical Award 2020 will be handed to Prof. Torzewski
08.11.2021
Nachdem Herr Prof. Jan Torzewski vom Klinikum Kempten letztes Jahr den 2. Platz beim German Medical Award erreicht hat, wird ihm der Preis am 16.11.2021 im Rahmen der MEDICA Düsseldorf und der diesjährigen Verleihung, überreicht.
2nd place for Prof. Torzewski at the GMA
18.11.2020
He was awarded in the category 'Medical Innovation Practices & Clinics - Cardiology' for the application of the innovative CRP apheresis after myocardial infarction. He prevailed against almost all colleagues, in particular also from university hospitals and heart centers.
Webinars
Second part of the second episode of our podcast has been published on YouTube
19.05.2022
Pentracast is the name of our new, informative podcast in which various employees, users and many others answer questions from our medical device consultant Henrike Weß.
This is the second part of the conversation between Henrike and Oliver
Second episode of our podcast has been published
08.04.2022
In the second episode Henrike has a chat with our colleague Oliver Wenske
Advanced training course on apheresis in acute COVID-19
06.04.2022
The event series of Brandenburg College For Nephrology starts of with the topic of CRP-Apheresis.
Lecture on the topic of CRP apheresis in severe COVID-19 courses at the BioBilanz seminar
20.01.22
At the web seminar "Biotech vs. SARS-CoV-2: A BioBilanz", Pentracor gave a lecture on CRP apheresis against COVID-19. The field report was presented by Managing Director Dr. Ahmed Sheriff.
The first episode of our podcast with Pentracor CEO Dr. Sheriff is online!
12.02.2022
Pentracast is the name of our new, informative podcast in which various employees, users and many others answer questions from our medical device consultant Henrike Weß.
Announcement: Web seminar with experience report on CRP apheresis against COVID-19
20.01.2022
We are represented with a lecture at the web seminar Biotech vs. SARS-CoV-2: A BioBilanz.
Events
Pentracor in the opening act of the Heart Days
20.05.2022
The Pentracor is at the Heart Days of the German Society of Cardiology 2022 on September 29th. – 01.10.2022 represented in Bonn.
Advanced training course on apheresis in acute COVID-19
06.04.2022
The event series of Brandenburg College For Nephrology starts of with the topic of CRP-Apheresis.
Lecture on the topic of CRP apheresis in severe COVID-19 courses at the BioBilanz seminar
20.01.22
At the web seminar "Biotech vs. SARS-CoV-2: A BioBilanz", Pentracor gave a lecture on CRP apheresis against COVID-19. The field report was presented by Managing Director Dr. Ahmed Sheriff.
Announcement: Web seminar with experience report on CRP apheresis against COVID-19
20.01.2022
We are represented with a lecture at the web seminar Biotech vs. SARS-CoV-2: A BioBilanz.
"Neutron" podcast presents CRP apheresis
21.05.2021
On the Neutron podcast, CRP apheresis was introduced and explained, and Dr. Ahmed Sheriff was interviewed. The focus was on the use of the therapy in COVID-19 patients.
bbb Lunch & Learn "COVID-19 patients successfully treated with CRP blood wash - a new therapy option in the pandemic."
19.05.2021
As part of the Lunch & Learn event series of the Biotechnologieverbund Berlin-Brandenburg (bbb), Dr. Ahmed Sheriff presented the PentraSorb® CRP and reported on its use at Klinikum Havelhöhe, where almost all COVID-19 patients are now treated with CRP apheresis. Afterwards there was an exciting discussion.
Other
Obituary: Rudolf Kunze
22.05.2023
On monday, May 22nd 2023 our great friend mentor and provider of ideas Dr. Rudolf Kunze passed away, peacefully. He leaves a great void. We miss him.
FDA grants designation as Breakthrough Device
28.11.2022
The FDA has granted PentraSorb CRP designation as a Breakthrough Device. A remarkable achievement.
Second part of the second episode of our podcast has been published on YouTube
19.05.2022
Pentracast is the name of our new, informative podcast in which various employees, users and many others answer questions from our medical device consultant Henrike Weß.
This is the second part of the conversation between Henrike and Oliver
Pentracor becomes a member of BVMed
10.08.2021
Pentracor recently joined the BVMed business association, which represents the interests of the German medtech industry and, in particular, medtech SMEs. BVMed represents around 220 industrial and commercial companies in the medical technology sector. Among others, the world's 20 largest medical device manufacturers in the consumer goods sector are organized in BVMed.
Pentracor donates Corona rapid tests to the Berliner Stadtmission
03.12.2020
To meet the strict hygiene requirements for emergency overnight stays, the Berliner Stadtmission has an increasing need for Corona rapid tests for guests and staff.
The 100th patient was successfully treated with CRP apheresis
14.10.2020
Der 100. Patient wurde dieser Tage mit der CRP-Apherese behandelt. Diese Behandlung lief im Rahmen der CABY1-Studie (CRP-Apherese nach koronarer Bypass-Operation) und wurde wie gewohnt sicher durchgeführt. Wir freuen uns, dass nun schon 100 Patienten von der Therapie profitieren konnten und hoffen, noch zahlreichen weiteren Menschen helfen zu können.
